Clinical trials: Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Oral AL01211 in healthy volunteers
- Trial name
- NCT04908462
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AceLink Therapeutics, Inc.
Autosomal Dominant Polycystic Kidney Disease
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
EuroCYST initiative aims to build a large, well-characterized cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) subjects who are followed in a longitudinal observational cohort study has the potential to identify…
- Trial name
- NCT02187432
- Where
- 14 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,100 people
- Sponsor
- Andreas L. Serra
Polycystic Kidney, Autosomal Dominant
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire pilot efficacy data in patients with autosomal dominant polycystic kidney disease…
- Trial name
- TEMPO 2:4 (NCT00413777)
- Testing
- Tolvaptan
- Where
- 11 sites in United States
- Volunteers
- 46 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Polycystic Kidney Diseases
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study is a prospective, randomized, open-label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression blocking capabilities (4), namely…
- Trial name
- NCT00286156
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
ADPKD, Autosomal Dominant Polycystic Kidney Disease
ADPKD Alterations in Hepatic Transporter Function
This is a single center, comparative cohort study to investigate alterations in hepatic transporter function in subjects with autosomal dominant polycystic kidney disease (ADPKD) compared to healthy subjects and subjects with…
- Conditions
- ADPKD, Autosomal Dominant Polycystic Kidney Disease, Renal Disease
- Trial name
- NCT03717883
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Polycystic Kidney Diseases
Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
Pathological features of Autosomal Dominant Polycystic Kidney disease (ADPKD) include enlarged kidney volume, a higher frequency of digestive diverticulitis and abdominal wall hernias.
- Trial name
- ADPKDPD (NCT03948113)
- Testing
- Dialysis
- Where
- France
- Volunteers
- 17,350 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
- Trial name
- NCT06345755
- Testing
- VX-407, Midazolam
- Where
- 2 sites in United States, Canada
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited cystic disorder characterised by the progressive degeneration of the renal parenchyma into cystic formations, with involvement of other organs to varying…
- Trial name
- NCT07535385
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Polycystic Kidney, Autosomal Dominant, Chronic Kidney Diseases
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct.
- Trial name
- POVA (NCT04363554)
- Testing
- Fluid intake, Thirsting
- Where
- Denmark
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
- Trial name
- NCT06747572
- Where
- 45 sites in United States, Belgium and 7 more
- Volunteers
- 401 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US.
- Trial name
- NCT03102632
- Testing
- High Water Intake
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Rogosin Institute
Adult Polycystic Kidney Disease, Kidney Neoplasms
Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function
The number of people with kidney disease is constantly rising and renal failure represents one of the major health care burdens globally.
- Conditions
- Adult Polycystic Kidney Disease, Kidney Neoplasms, Kidney Dysfunction
- Trial name
- NCT03442647
- Testing
- sinistrin clearance dynamic measurement
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Thomas Mueller
Autosomal Dominant Polycystic Kidney Disease
Intrarenal Microvasculature in ADPKD
The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and healthy…
- Trial name
- NCT05288998
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Uncontrolled Hypertension, Autosomal Dominant Polycystic Kidney Disease
Renal Denervation in ADPKD- RDN-ADPKD Study
RDN-ADPKD is a prospective, randomized (1:1, central randomization), single-center, hypothesis-generating, feasibility study. The purpose of the RDN-ADPKD study is to demonstrate efficacy and document safety of renal denervation…
- Conditions
- Uncontrolled Hypertension, Autosomal Dominant Polycystic Kidney Disease, Renal Denervation
- Trial name
- RDN-ADPKD (NCT05460169)
- Testing
- Renal denervation
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Study of Tamibarotene in Patients With ADPKD
Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease
- Trial name
- NCT06289998
- Testing
- Tamibarotene
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Rege Nephro Co., Ltd.
Autosomal Dominant Polycystic Kidney Disease
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common single gene disorder that is potentially fatal. ADPKD is caused by mutations in either of two genes (PKD1, PKD2).
- Trial name
- NCT00759369
- Testing
- Water prescription
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas
Autosomal Dominant Polycystic Kidney Disease
The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain
This study will test the safety and efficacy of the Vessix Renal Denervation system in the reduction of pain in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Trial name
- NCT02746419
- Testing
- Vessix
- Sponsor
- University of Chicago
Kidney Disease
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given.
- Trial name
- NCT06734234
- Testing
- GSK4771261
- Where
- 23 sites in United States, Belgium and 6 more
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
ADPKD
Short Term Induction of Ketosis in PKD
Recently, it has been shown that ketose-inducing dietary interventions slow disease progression in animal models of polycystic kidney disease (PKD), even when the state of ketosis is only induced for a short period of time.
- Trial name
- RESET-PKD (NCT04472624)
- Testing
- Fasting, Ketogenic diet
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Cologne
Autosomal Dominant Polycystic Kidney, ADPKD
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD.
- Trial name
- FALCON (NCT03918447)
- Testing
- Bardoxolone methyl oral capsule
- Where
- 137 sites in United States, Australia and 8 more
- Volunteers
- 667 people
- Sponsor
- Biogen